Likewise, NSCLC patients with overlapping of KRAS and STK11/LKB1 mutations’ have showed a higher clinical sensitivity for ICIs due to epigenetic inhibition of stimulator of INF genes (STING) [24,29,42]. Here, STK11 is linked to non-small cell lung carcinoma.